About Us
Meet the minds behind Radyx
Meet the minds behind RAdyx
Our Team
CDO
Freddie Ann Hoffman, MD
Freddie Ann Hoffman, MD
Freddie Ann Hoffman, MD
CoO
Staci J Eisner
Staci J Eisner
Senior Advisor
Jolene Anderson
Jolene Anderson
Jolene Anderson
Jolene Anderson
CEO/CSO
Stephen Morrissey, OMD
Stephen Morrissey, OMD
CMO
Steve R Kishter, MD, DDS
Steve R Kishter, MD, DDS
CfO
Richard Samuelson, CFA
Richard Samuelson, CFA
Our Team
CHIEF OF STAFF
Jenny Morrissey, L.Ac.
Dr. Stephen Morrissey brings 35+ years of clinical and commercial expertise in botanical medicine and targeted therapeutic development. He created a proprietary selection process to optimize plant-based medicines for complex disease targets, backed by 10 validated research studies - five human clinical trials, four in vitro bioassays, and a lab study - all showing statistically significant efficacy. He holds four issued U.S. patents spanning immune function and physical performance, two with Dr Wang Ruo Tao.
A serial entrepreneur, Dr. Morrissey founded Cortex Scientific Botanicals (CSB), which has supplied botanical ingredients for over two decades to major multinational pharma and consumer health companies. He spent a year negotiating five supply chain contracts with Novartis, leading a ten-person team overseas to audit CSB’s manufacturing infrastructure before all five contracts were executed.
CSB will direct procurement and R&D for Radyx’s lead asset, CG1.4. Dr. Morrissey has overseen the sourcing and manufacture of over 300 tons of concentrated plant-based extracts and developed more than 40 health products. His extensive collaborations with international research institutions and universities have helped advance the quality, safety, and standardization required for botanical drug development. he was on the Board of the American Herbal Products Association and was Chair of the Oriental Medicine department at Bastyr University. He earned his B.S. in Business from the University of Denver and his Doctorate in Oriental Medicine from the California Acupuncture College.
Chief Executive Officer & Chief Scientific officer
Stephen Morrissey, OMD
Chief Executive Officer & Chief Scientific officer
Stephen Morrissey, OMD
Dr. Freddie Ann Hoffman serves as the Chief Development Officer of our company. She is also the CEO of HeteroGeneity, LLC, a scientific and regulatory consulting firm she founded in 2003. Dr. Hoffman has an extensive background in both the public and private sectors including her role as Chief of the Cytokines, Growth Factors, and Oncologic Products Branch at the FDA Center for Biologics Evaluation and Research (CBER). During her time at the FDA, she led a team that played a crucial role in the licensing of 15 biologic drugs. She also served in the Office of the FDA Commissioner, as the Deputy Director of the Medicine Branch, where she chaired the Agency’s Working Group on Botanical drugs, producing the Agency’s guidance on botanical drug development. Dr. Hoffman received a Bachelor of Science in Chemistry at UCLA, a Doctorate of Medicine and residency at US Davis, and completed a fellowship in pediatric hematology-oncology at the National Cancer Institute, where she conducted significant clinical and laboratory research. Following retirement from the US Public Health Service as a Captain, she served as the senior director for New Technology and Product Development at Pfizer-Warner Lambert Consumer Health Care. Her company, HeteroGeneity, assisted sponsors in achieving the first two FDA New Drug Approvals for prescription botanical drugs in the United States.
Chief Development officer
Freddie Ann Hoffman, MD
Chief Development officer
Freddie Ann Hoffman, MD
Ms. Staci J. Eisner serves as Chief Operations Officer of Radyx Bioscience. She has worked as Director of Quality Assurance and Regulatory Affairs at United States, Japanese, and Swiss dose-form and extract manufacturers. Ms. Eisner has also been extensively involved with the Institute for Nutraceutical Advancement’s Methods Validation Program, the Board of Trustees of the American Herbal Products Association (AHPA), and the NSF/ANSI Joint Task Force on Dietary Supplements.
As VP of Quality and Regulatory Affairs at Cortex Scientific Botanicals, she manages the production of quality ingredients backed by over twenty years of global industry experience. Her work ensures that Cortex meets the rigorous standards required by customers across the sector, from specialized dietary supplement companies to multinational consumer health and pharmaceutical leaders.
Ms. Eisner has served as managing editor of three technical documents for AHPA, focusing on industry‑wide issues of quality assurance related to manufacturing, marker compounds, and standardization of botanicals. She graduated with honors in both chemistry and biochemistry of natural products at Cornell University.
Chief Operating officer
Staci J Eisner
Chief Operating officer
Chief Operating officer
Staci J Eisner
Ms. Staci J. Eisner serves as Chief Operations Officer of Radyx Bioscience. She has worked as Director of Quality Assurance and Regulatory Affairs at United States, Japanese, and Swiss dose-form and extract manufacturers. Ms. Eisner has also been extensively involved with the Institute for Nutraceutical Advancement’s Methods Validation Program, the Board of Trustees of the American Herbal Products Association (AHPA), and the NSF/ANSI Joint Task Force on Dietary Supplements.
As VP of Quality and Regulatory Affairs at Cortex Scientific Botanicals, she manages the production of quality ingredients backed by over twenty years of global industry experience. Her work ensures that Cortex meets the rigorous standards required by customers across the sector, from specialized dietary supplement companies to multinational consumer health and pharmaceutical leaders.
Ms. Eisner has served as managing editor of three technical documents for AHPA, focusing on industry‑wide issues of quality assurance related to manufacturing, marker compounds, and standardization of botanicals. She graduated with honors in both chemistry and biochemistry of natural products at Cornell University.
Dr. Steven Kishter is our Chief Medical Officer. He is also CEO of The Avenue 16 Group LLC, a business development consultancy with a focus on naturally complex drugs. He holds an undergraduate degree in Neuroscience from McGill University and began a research career in the NCI Laboratory of Tumor Biology, led by Robert A Gallo, MD and then later in the NCI Pediatric Oncology Branch. His clinical training includes a doctorate of dental surgery from the U of Maryland and a medical degree from Albany School of Medicine. During a fellowship in the NCI Surgical Oncology Branch, he worked both clinically and in the lab. His broad clinical and drug development experience includes the design, implementation, and analyses of clinical study protocols for drugs and biologics under IND, as well as the surgical procedures and care of patients with cancer, AIDS, and other conditions treated at the National Institutes of Health Clinical Center. Returning to the U of Maryland, Dr. Kishter trained and received board certification in oral-maxillofacial surgery. Moving to the private sector, he became the Medical Director for the Advil® franchise at Wyeth Consumer Healthcare, where he also served on the company’s New Technology Search Team before returning to the DC area to practice oral-max surgery, which he continues to do part-time, as he remains involved in new product development as a Medical-Clinical expert.
Chief medical officer
Steve R Kishter, MD, DDS
Chief medical officer
Steve R Kishter, MD, DDS
Mr. Richard Samuelson serves as the Chief Financial Officer of our company. He spent the first phase of his career in investment banking, primarily in Asia, beginning as an analyst in 1991 and rising to Head of Research and then Head of Equity for UBS Korea, where revenues grew from $1 million to $60 million under his leadership. He was subsequently promoted to Managing Director for Japan Equity at UBS and then for all of Asia at BNP Paribas, with UBS Tokyo revenues growing from over $200 million to more than $600 million during his tenure. As Vice Chairman of the American Chamber of Commerce in Korea, he advised the Korean government on capital market reform and briefed Treasury Secretary Robert Rubin, Deputy Secretary Larry Summers, and Federal Reserve Governor Roger Ferguson during the Asian financial crisis. Returning to the United States, Mr. Samuelson became active in technology and angel investing through the Keiretsu Forum, leading financial due diligence across biotech, software, and manufacturing, and serving on the investment review committee for the first Keiretsu Capital Fund. His board roles have produced multiple exits, including Kineta, Inc., an oncology company that reverse merged into NASDAQ-listed Yumanity, along with Immunomics, Aprea Therapeutics, Otosense, EVConnect, and Bird Buffer LLC. In 2019 he co-founded SWAN Venture Group, which has facilitated more than $30 million of Japanese capital into early-stage US and Canadian companies. He currently serves in operational CFO roles at Loopr.AI and Indicio and is a principal at FocusCFO. Mr. Samuelson is a graduate of Wharton (Finance) and Yale (BA, English Literature) and holds the CFA, CAIA, FRM, SIE, and FDP certifications.
Chief Financial officer
Richard Samuelson, CFA
Chief Financial officer
Richard Samuelson, CFA
Jenny Morrissey, L.Ac., Dipl.Ac. (NCCAOM), is co-founder and Chief of Staff at Radyx Bioscience. She has worked since 1991 developing herbal supplements with her husband, Dr. Stephen Morrissey, and together they were serial entrepreneurs including founding Cortex Scientific Botanicals and Radyx Bioscience. Ms. Morrissey has been actively involved in designing and refining systems for evaluating natural substances and turning clinical insights into products. At Radyx, she focuses on supporting people and systems so the organization can move forward—combining strategy, operations, and behind-the-scenes work.
She has been practicing Acupuncture and Oriental Medicine for over 30 years and has served as Chair of the Oriental Medicine Department and on the academic and clinical faculty at Bastyr University in Redmond, Washington. Ms. Morrissey has a BS from The Evergreen State College and graduated from the NW Institute of Acupuncture and Oriental Medicine. She has trained and volunteered with Acupuncturists Without Borders, at PTSD clinics at Veterans Helping Veterans Now, and participated in the Colorado Acupuncture Medical Reserve Corps (CAMRC) deploying as support to local disasters.
Chief OF STAFF
Jenny Boehm Morrissey, L.Ac.
Chief oF Staff
Jenny Boehm Morrissey, L.Ac.
Jolene Anderson is a former Chapter President for the Keiretsu Forum Boise Chapter, an impact investor, fund advisor, frequent judge and speaker for many life science investor events, due diligence team leader, seasoned business executive and serial entrepreneur, media founder, and speaker/educator for global health. With a background in business brokerage and appraisal, Ms. Anderson gained experience in advising small business owners on startup financing, growth strategies, marketing, and exit planning. As the founder of JMR Consulting, she has focused her efforts on advising companies as a Strategist, Investor Relations, and Business Facilitator full-time since 2012. She is the founder of a global wellness company and produced events on functional medicine, fem aging, and integrated health.
Her client list includes edu-tech, biotech, technology, real estate, finance, data integrity, wellness, hospitality, material science, and agriculture companies. She advises clients and groups on pitching to angel organizations, media strategies, and financing resources. As Co-Chair of the Angel Capital Association Impact Syndication Group and member of the ACA Life Science Committee, she plays a key role in the angel capital ecosystem. She is the current SAB Chair for the Chris Elliott Fund for Brain Cancer Research (www.EndBrainCancer.org), a Board of Directors member for KinectCapital.org, a Board member of The Evergreen Bioscience Innovation Cluster, and incoming President of the Rotary Club of Magnolia and other worthy organizations. In April 2026, Ms. Anderson received the Keiretsu Forum NW/Rockies Member of the Year award at the K4 NW/Rockies Investor Expo.
Senior Advisor
Jolene Anderson
Senior Advisor
Jolene Anderson
Introducing CG1.4
Discover the future of inflammation treatment with CG1.4, our innovative polymolecular drug candidate. Designed to address the limitations of traditional biologics, CG1.4 offers a promising solution for patients seeking relief from inflammatory and autoimmune diseases. Learn more about how CG1.4 could transform the lives of patients.
The Future of Inflammatory Disease Treatment
Learn more
Partners in Innovation
Partners in Innovation
Invest in a company pioneering a new approach to autoimmune disease treatment. Every investment helps bring patients closer to a safer, more effective option than what exists today. Join us at a pivotal moment in that journey.
Invest in a brighter future
Invest in a brighter future
Join us
Join us
